^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Immunoprint®

    Company:
    NeraCare
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    The immunoprint test provides a genomic-based, comprehensive, individualized risk assessment for stage I-II melanoma patients. The test uses immunohistochemistry (IHC) to measure the expression of seven proteins - comprising of five risk markers (Bax, Bcl-X, COX-2, PTEN and presence of CD20-positive B-lymphocytes) and two ‘protective’ markers (loss of MTAP and loss of ß-catenin) in a tumor sample after it has been removed by surgery or biopsy.
    Cancer:
    Melanoma
    Gene:
    BAX (BCL2-associated X protein), BCL2L1 (BCL2-like 1), CD20 (Membrane Spanning 4-Domains A1), CTNNB1 (Catenin (cadherin-associated protein), beta 1), MT-CO2 (Mitochondrially Encoded Cytochrome C Oxidase II), MTAP (Methylthioadenosine Phosphorylase)
    See More ...
    Method:
    Immunohistochemistry (IHC)